These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Therapeutic Strategies for Huntington's Disease. Mrzljak L; Munoz-Sanjuan I Curr Top Behav Neurosci; 2015; 22():161-201. PubMed ID: 24277342 [TBL] [Abstract][Full Text] [Related]
24. Mitochondrial fragmentation in neuronal degeneration: Toward an understanding of HD striatal susceptibility. Cherubini M; Ginés S Biochem Biophys Res Commun; 2017 Feb; 483(4):1063-1068. PubMed ID: 27514446 [TBL] [Abstract][Full Text] [Related]
29. Targeting mutant huntingtin for the development of disease-modifying therapy. Appl T; Kaltenbach L; Lo DC; Terstappen GC Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050 [TBL] [Abstract][Full Text] [Related]
30. Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis. Schackel S; Pauly MC; Piroth T; Nikkhah G; Döbrössy MD Behav Brain Res; 2013 Nov; 256():56-63. PubMed ID: 23916743 [TBL] [Abstract][Full Text] [Related]
31. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Freeman TB; Cicchetti F; Hauser RA; Deacon TW; Li XJ; Hersch SM; Nauert GM; Sanberg PR; Kordower JH; Saporta S; Isacson O Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13877-82. PubMed ID: 11106399 [TBL] [Abstract][Full Text] [Related]
32. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Peschanski M; Cesaro P; Hantraye P Neuroscience; 1995 Sep; 68(2):273-85. PubMed ID: 7477940 [TBL] [Abstract][Full Text] [Related]
33. Selective degeneration in YAC mouse models of Huntington disease. Van Raamsdonk JM; Warby SC; Hayden MR Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936 [TBL] [Abstract][Full Text] [Related]
34. The Biology of Huntingtin. Saudou F; Humbert S Neuron; 2016 Mar; 89(5):910-26. PubMed ID: 26938440 [TBL] [Abstract][Full Text] [Related]
35. Recent insights into the molecular pathogenesis of Huntington disease. Leavitt BR; Wellington CL; Hayden MR Semin Neurol; 1999; 19(4):385-95. PubMed ID: 10716661 [TBL] [Abstract][Full Text] [Related]
37. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573 [TBL] [Abstract][Full Text] [Related]
38. Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons. Garcia Jareño P; Bartley OJM; Precious SV; Rosser AE; Lelos MJ Int Rev Neurobiol; 2022; 166():1-48. PubMed ID: 36424090 [TBL] [Abstract][Full Text] [Related]